Troriluzole

Troriluzole
Clinical data
Other names	Vyglxia, Trigriluzole, BHV-4157, FC-4157
Routes of; administration	By mouth
ATC code	N07XX23 (WHO) ;
Identifiers
	IUPAC name 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide;
CAS Number	1926203-09-9;
PubChem CID	121488186;
DrugBank	DB15079;
ChemSpider	58828005;
UNII	S7H48S6K7H;
KEGG	D11414;
ChEMBL	ChEMBL4297586;
Chemical and physical data
Formula	C15H16F3N5O4S
Molar mass	419.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN;
	InChI InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25); Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N;

Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD),^[1] obsessive–compulsive disorder (OCD),^[2]^[3] and glioblastoma.^[4] It is a prodrug formulation of the medication riluzole.^[2]^[4]

Other namesVyglxia, Trigriluzole, BHV-4157, FC-4157

Quick facts Clinical data, Other names ...

Close

Pharmacology

Clinical data

Other names	Vyglxia, Trigriluzole, BHV-4157, FC-4157
Routes of administration	By mouth
ATC code	N07XX23 (WHO)
Identifiers
IUPAC name 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
CAS Number	1926203-09-9
PubChem CID	121488186
DrugBank	DB15079
ChemSpider	58828005
UNII	S7H48S6K7H
KEGG	D11414
ChEMBL	ChEMBL4297586
Chemical and physical data
Formula	C₁₅H₁₆F₃N₅O₄S
Molar mass	419.38 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
InChI InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25) Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N